IP Library › Granted Patent US 12,440,585
Granted Patent B2
US 12,440,585 · App. 18/640,169 · Granted Oct 14, 2025

Zwitterionic metal chelators

Inventors: John V. Frangioni (Weston, MA); Wolfgang Maison (Winsen, DE)
Assignee: Curadel Surgical Innovations, Inc.
A61K51/0482A61B6/037A61K49/0032A61K51/0478A61K51/082A61K2121/00A61K2123/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,585
App. No.
18/640,169
Granted
Oct 14, 2025
Kind
B2
Abstract

The present invention relates to zwitterionic metal chelators and their use as imaging, diagnostic, chemical processing, and treatment agents. These zwitterionic metal chelators have desirable properties that maximize solubility in aqueous environments, minimize non-specific interactions, and retain the ability to target thus resulting in an improved performance in a variety of medical, agricultural, and chemical processes. In in vivo and medical applications, zwitterionic metal chelators improve the signal-to-background ratio and therapeutic window as compared to other metal chelators while retaining high stability.

Claims (24)

1. A zwitterionic metal chelator complex comprising a metal chelator having zwitterionic groups and a metal or metal isotope selected from the group consisting of a radionuclide, a label, a paramagnetic metal and a heavy metal,

wherein the metal chelator is a derivative of DOTA having the formula:

wherein ZWI is an N-oxide zwitterionic group; and each instance of W and Y independently is a linking group.

2. The zwitterionic metal chelator complex according to claim 1 , further comprising one or more targeting vectors; wherein the one or more targeting vectors are cRGD, KUE, PSMA-617, FAPI, octreotide, bombesin, or a homo- or hetero-dimer formed from their combination.

3. The zwitterionic metal chelator complex according to claim 1 , wherein the metal or metal isotope is Pb, Zr, Cu, Ga, In, Y, Gd, Lu, Ac or Tb.

4. An imaging agent comprising a zwitterionic metal chelator complex according to claim 1 .

5. A method of imaging cells, tissues, or organs, the method comprising:

(a) contacting cells with an imaging agent according to claim 4 ; and

(b) imaging the cells, tissues, or organs using positron emission tomography (PET), single-photon emission computerized tomography (SPECT), or magnetic resonance imaging (MRI).

6. A therapeutic agent comprising a zwitterionic metal chelator complex according to claim 1 And a pharmaceutically acceptable carrier or excipient.

7. A method of treating a cancerous condition in a subject in need thereof, the method comprising:

contacting cancer cells in the subject with an effective amount of a therapeutic agent according to claim 6 ,

wherein the metal atom complexed to the zwitterionic metal chelator is:

a radioactive metal isotope known to emit ionizing radiation that results in the death of cells that take up the analogs;

or a non-radioactive metal that is capable of releasing cytotoxic radiation upon irradiation with alpha emission, beta emission, neutron capture, or a combination thereof.

8. A method of treating a cancer by administering an effective amount of a therapeutic agent according to claim 6 , wherein the method comprises a step to diagnose the cancer and a step of administering the therapeutic agent to a subject determined to be in need thereof;

wherein the step to diagnose the cancer comprises:

contacting cells, tissues or organs of a subject with an imaging agent,

imaging the cells, tissues, or organs of the subject using positron emission tomography (PET), single-photon emission computerized tomography (SPECT), or magnetic resonance imaging (MRI), and

diagnosing the cancer in the cells tissues, or organs of the subject based on imaging data collected;

and wherein the metal atom complexed to the zwitterionic metal chelator is:

a radioactive metal isotope known to emit ionizing radiation that results in the death of cells that take up the analogs;

or a non-radioactive metal that is capable of releasing cytotoxic radiation upon irradiation with alpha emission, beta emission, neutron capture, or a combination thereof.

9. The zwitterionic metal chelator complex according to claim 1 , wherein the metal chelator is a derivative of DOTA having the formula:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2025
From: FRANGIONI, JOHN V.; MAISON, WOLFGANG
To: CURADEL SURGICAL INNOVATIONS, INC.
Reel/Frame 071639/0155 →
Continuity (2)
Provisional Application 63538038 · Sep 12, 2023
Related Publication 20250082792A1 · Mar 13, 2025
References Cited (100)
US 6083485A · Licha et al. · 2000 [cited by applicant]
US 6258340B1 · Licha et al. · 2001 [cited by applicant]
US 6440389B1 · Rabito · 2002 [cited by applicant]
US 6913743B2 · Licha et al. · 2005 [cited by applicant]
US 6926885B2 · Licha et al. · 2005 [cited by applicant]
US 7025949B2 · Licha et al. · 2006 [cited by applicant]
US 7445767B2 · Licha et al. · 2008 [cited by applicant]
US 7582483B2 · Mizutani et al. · 2009 [cited by applicant]
US 7655217B2 · Licha et al. · 2010 [cited by applicant]
US 7682603B2 · Hammer et al. · 2010 [cited by applicant]
US 8173819B2 · Rajopadhye et al. · 2012 [cited by applicant]
US 8268014B2 · Frohling · 2012 [cited by applicant]
US 8460639B2 · Nomoto et al. · 2013 [cited by applicant]
US 10201621B2 · Frangioni et al. · 2019 [cited by applicant]
US 11279698B2 · Babich et al. · 2022 [cited by applicant]
US 20010055567A1 · Licha et al. · 2001 [cited by applicant]
US 20030026762A1 · Malmros et al. · 2003 [cited by applicant]
US 20030026763A1 · Licha et al. · 2003 [cited by applicant]
US 20030170179A1 · Licha et al. · 2003 [cited by applicant]
US 20040028611A1 · Frangioni · 2004 [cited by applicant]
US 20040029837A1 · Fries et al. · 2004 [cited by applicant]
US 20040062713A1 · Matsuo et al. · 2004 [cited by applicant]
US 20050106106A1 · Licha et al. · 2005 [cited by applicant]
US 20050169844A1 · Licha et al. · 2005 [cited by applicant]
US 20060040400A1 · Mizutani et al. · 2006 [cited by applicant]
US 20060165598A1 · Licha et al. · 2006 [cited by applicant]
US 20060165599A1 · Licha et al. · 2006 [cited by applicant]
US 20060275209A1 · Schweiger et al. · 2006 [cited by applicant]
US 20070292883A1 · Ossovskaya et al. · 2007 [cited by applicant]
US 20080308744A1 · Frangioni et al. · 2008 [cited by applicant]
US 20080318336A1 · Scherninski et al. · 2008 [cited by applicant]
US 20090269277A1 · Chang et al. · 2009 [cited by applicant]
US 20100035871A1 · Stack et al. · 2010 [cited by applicant]
US 20100129293A1 · Licha et al. · 2010 [cited by applicant]
US 20100323389A1 · Xu et al. · 2010 [cited by applicant]
US 20120017931A1 · Frohling · 2012 [cited by applicant]
US 20120045851A1 · Scherninski et al. · 2012 [cited by applicant]
US 20130030282A1 · Margel et al. · 2013 [cited by applicant]
US 20140063097A1 · Liu et al. · 2014 [cited by applicant]
US 20150209451A1 · Frangioni et al. · 2015 [cited by applicant]
US 20170290927A1 · Frangioni et al. · 2017 [cited by applicant]
US 20220387631A1 · Frangioni et al. · 2022 [cited by applicant]
JP H5150395A · 1993 [cited by applicant]
JP 200095758A · 2000 [cited by applicant]
JP 2005524072A · 2005 [cited by applicant]
JP 2007508282A · 2007 [cited by applicant]
JP 2009507035A · 2009 [cited by applicant]
JP 2010169677A · 2010 [cited by applicant]
JP 2011503067A · 2011 [cited by applicant]
JP 2012524153A · 2012 [cited by applicant]
JP 2013523725A · 2013 [cited by applicant]
JP 2013199477A · 2013 [cited by applicant]
WO 2005082423A2 · 2005 [cited by applicant]
WO 2007017602A2 · 2007 [cited by applicant]
WO 2009061473A2 · 2009 [cited by applicant]
WO 2010091243A1 · 2010 [cited by applicant]
WO 2010121163A2 · 2010 [cited by applicant]
WO 2012063028A1 · 2012 [cited by applicant]
WO 2015066290A1 · 2015 [cited by applicant]
Henry et al. J. Label Compd Radiopharm. 2017:60 (supp. 1):S516. (Year: 2017). [cited by examiner]
Kriemen et al. Chem. Asian J. 2014, 9, 2197-2204. (Year: 2014). [cited by examiner]
Li et al. Chem. Rev. 2022, 122, 17072-17154. (Year: 2022). [cited by examiner]
Kunikowska et al. Semin. Nucl. Med. 2019, 50:171-176. (Year: 2019). [cited by examiner]
Choi et al. Nat. Biotech. 2013, 148-154. (Year: 2013). [cited by examiner]
Ciba-Geigy AG, “Use of dyes for shading during optical brightening of polyester and polyacrylonitrile substrates”, Research Disclosure, 1982, vol. 216, Article No. 21611, pp. 107-109. [cited by applicant]
Yuan, L. et al. “A unique class of near-infrared functional fluorescent dyes with carboxylic-acid-modulated fluorescence On/Off switching rational design, synthesis, optical properties, theoretical calculations, and app… [cited by applicant]
James, N.S. et al., “Evaluation of polymethine dyes as potential probes for near infrared fluorescence imaging of tumors: Part 1”, Theranostics, Aug. 2013, vol. 3, No. 9, pp. 692-702. [cited by applicant]
Quek, C.-H. et al. “Near-infrared fluorescent nanoprobes for in vivo optical imaging”, Nanomaterials, 2012, vol. 2, No. 2, pp. 92-112. [cited by applicant]
Ashitate, Y., et al. “Simultaneous mapping of pan and sentinel lymph nodes for real-time image guided surgery”, Teranostics, Apr. 2014, vol. 4, No. 7, pp. 693-700. [cited by applicant]
Amiot, C. L. et al., “Near-infrared fluorescent materials for sensing of biological targets”, Sensors, 2008, vol. 8, No. 5, pp. 3082-3105. [cited by applicant]
Tibre, A. G. J. et al., “Imaging technique implemented in CellTracks system,” Cytometry, 2002, vol. 47, No. 4, pp. 248-255. [cited by applicant]
Chemical Physics Letters, Mar. 1996, vol. 250 pp. 261-265. [cited by applicant]
Gibbs “Near infrared fluorescence for image-guided surgery” Quant Imaging Med Surg, Jan. 1, 2012, pp. 177-187. [cited by applicant]
Journal of Photopolymer Science and Technology, 2000, vol. 13, No. 2, pp. 183-186. [cited by applicant]
Proceedings of SPIE, 2011, vol. 8114, pp. 81140 T-1 to 81140 T-9. [cited by applicant]
Sano, K. “Short PEG-linkers improve the performance of targeted, activable monoclonal antibody-indocyanine green optical imaging probes” Bioconjugate Chemistry, 2013 24(5), pp. 811-816. [cited by applicant]
European Journal of Medicinal Chemistry, 2012, vol. 54, pp. 647-659. [cited by applicant]
Office Action issued in Japanese Patent Application No. JP 2016-552234, dated Oct. 21, 2020. [cited by applicant]
Stoermer U et al., “Kann der metachromatische Index eine Hilfe bei der Krebsdiagnose sein?// The metachromatic index—an aid in cancer diagnosis?”, Acta Histochemica, vol. 84, No. 1, Jan. 1, 1988, pp. 31-39. [cited by applicant]
Zimmermann U et al., “[Staining behavior and applicability of spectrally pure Capriblue GN, Stella Blue, Oxonin and Punky Blue]”, Acta Histochemica, 1983, vol. 72, No. 1, pp. 55-69. [cited by applicant]
Winer, J. H., et al., “Intraoperative Localization of Insulinoma and Normal Pancreas Using Invisible Near-Infrared Fluorescent Light”, Annals of Surgical Oncology, vol. 17, No. 4, Dec. 22, 2009, pp. 1094-1100. [cited by applicant]
Kate, P. G., et al., “Rapid and Selective Targeting of Heterogeneous Pancreatic Neuroendocrine Tumors”, iScience, Apr. 24, 2020, pp. 101006-101006. [cited by applicant]
Extended European Search Report dated Feb. 13, 2023, issued during the prosecution of European Patent Application No. EP 22188587.4. [cited by applicant]
Ghanadzadeh et al. (Spectrochimica Acta Part A 2009, 73, 324-329). [cited by applicant]
Dao et al. (Australas. Phys. Eng. Sci. Med. 2004, 27, 224-229). [cited by applicant]
Sloviter (Cancer Res. 1949, 9, 677-680). [cited by applicant]
International Search Report issued in PCT/US2014/063104, dated Feb. 26, 2015. [cited by applicant]
International Search Report issued in PCT/US2014/063097, dated Apr. 10, 2015. [cited by applicant]
A. Swierzewski et. al., Dota-and DFO-Based Zwitterionic Chelators for 89ZR-PET), Universitat Hamburg, Fachbereich Chemie, Institute fur Pharmazie. [cited by applicant]
T. Lindner, et al., Radioligands Targeting Fibroblast Activation Protein (FAP)), Cancer 2021, 13, 5744. [cited by applicant]
Valk et al. (Clin. Cancer Res. 2020, 26, 3990-3998 and supplemental data). [cited by applicant]
Bao et al., (Chem. Commun. 2017, 53, 1611-1614. [cited by applicant]
Mulder et al. (Am Jnl. Nucl. Med. Mol. Imaging 2018, 8, 282-291). [cited by applicant]
De Jalon et al. (Mol. Imaging and Biol. 2023, 25, 144-155. [cited by applicant]
Hyun et al. (Mol. Imaging Biol. 2016, 18, 52-61). [cited by applicant]
Hensbergen et al. (Bioconj. Chem. 2020, 31, 375-395). [cited by applicant]
Njiojob et al. (J. Med. Chem. 2015, 58, 2845-2854). [cited by applicant]
Van Rymenant et al. (Frontier Chem. 2021, Article 640566, p. 1-12. [cited by applicant]
Slania et al. (J. Med. Chem 2021, 64, 4059-4070. [cited by applicant]
Park et al., Rapid & Selective Targeting of Heterogenous Pancreatic Neuroendocrine Tumors, IScience, 23, 101006, Apr. 24, 2020. [cited by applicant]